Share on StockTwits

Orexigen Therapeutics (NASDAQ:OREX) is set to post its quarterly earnings results on Thursday, May 8th. Investors that are interested in registering for the company’s conference call can do so using this link.

Orexigen Therapeutics (NASDAQ:OREX) last released its earnings data on Wednesday, March 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.02. The company had revenue of $857.00 million for the quarter, compared to the consensus estimate of $900.00 million. During the same quarter in the previous year, the company posted ($0.41) earnings per share. On average, analysts expect Orexigen Therapeutics to post $0.08 EPS for the current fiscal year and $-0.17 EPS for the next fiscal year.

Orexigen Therapeutics (NASDAQ:OREX) opened at 5.48 on Wednesday. Orexigen Therapeutics has a one year low of $4.60 and a one year high of $7.84. The stock has a 50-day moving average of $6.00 and a 200-day moving average of $6.10. The company’s market cap is $611.2 million.

On the ratings front, analysts at Wells Fargo & Co. initiated coverage on shares of Orexigen Therapeutics in a research note on Thursday, April 24th. They set an “outperform” rating on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $9.60.

Orexigen Therapeutics, Inc develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body’s efforts to compensate for weight loss.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.